SF1126   Click here for help

GtoPdb Ligand ID: 12619

Synonyms: SF 1126 | SF-1126
Compound class: Synthetic organic
Comment: SF1126 is an RGDS-conjugated prodrug of the phosphatidylinositol 3-kinase (PI3K) inhibitor LY 294002 [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 20
Hydrogen bond donors 9
Rotatable bonds 28
Topological polar surface area 346.68
Molecular weight 852.85
XLogP -2.95
No. Lipinski's rules broken 4
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C1=CC=C(C=C1)C2=C3C(=CC=C2)C(=O)C=C([NH+]4CCOCC4COC(=O)CCC(=O)NC(CCCNC(=N)[NH3+])C(=O)NC([H])C(=O)NC(CC(=O)[O-])C(=O)NC(CO)C(=O)[O-])O3
Isomeric SMILES [H]C(NC(=O)C(CCCNC([NH3+])=N)NC(=O)CCC(=O)OCC1COCC[NH+]1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4)C(=O)NC(CC([O-])=O)C(=O)NC(CO)C([O-])=O
InChI InChI=1S/C39H48N8O14/c40-39(41)42-13-5-10-26(36(55)43-18-31(51)45-27(16-33(52)53)37(56)46-28(19-48)38(57)58)44-30(50)11-12-34(54)60-21-23-20-59-15-14-47(23)32-17-29(49)25-9-4-8-24(35(25)61-32)22-6-2-1-3-7-22/h1-4,6-9,17,23,26-28,48H,5,10-16,18-21H2,(H,43,55)(H,44,50)(H,45,51)(H,46,56)(H,52,53)(H,57,58)(H4,40,41,42)
InChI Key FKRJGCSSZMNDDY-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
SF1126 was advanced to clinical studies for advanced solid tumours, but most of these were terminated due to low patient accrual.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03059147 Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma Phase 1 Interventional SignalRX Pharmaceuticals, Inc.
NCT02337309 SF1126 for Patients With Relapsed or Refractory Neuroblastoma Phase 1 Interventional New Approaches to Neuroblastoma Therapy Consortium
NCT02644122 SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes Phase 2 Interventional University of California, San Diego
NCT00907205 A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors Phase 1 Interventional Semafore Pharmaceuticals